Question 1

What amounts did the nesiritide and carperitide studies use?

Accepted Answer

The nesiritide trials report their amounts as infusion rates, and they sit in a narrow band. VMAC, the study designed to answer the FDA's 1999 questions, chose a dosing regimen, 0.2 microgram/kg bolus followed by 0.01 microg/kg/min continuous infusion, to give rapid onset without a high incidence of symptomatic hypotension. A bolus is a single quick injection, and the infusion then runs continuously. PRECEDENT randomized 255 patients to 1 of 2 doses of intravenous nesiritide (0.015 or 0.03 microg/kg/min) or dobutamine (> or =5 microg/kg/min). After heart valve surgery, a pilot trial gave a 72-hour infusion of 0.01 mcg/kg/min to 9 patients, against placebo in 10. ASCEND-HF gave nesiritide or placebo for 24 to 168 hours, and its summary states no rate. ROSE-AHF gave a low dose for 72 hours to patients with kidney dysfunction, and its summaries state no rate either. For carperitide, the 2025 summary gives no amount, and the figures sit inside the nine studies it pooled. These are rates chosen for monitored hospital patients, reported as study parameters rather than guidance.

Question 2

Who received these infusions?

Accepted Answer

Almost all were adults admitted to hospital with acute decompensated heart failure, a sudden worsening in which fluid backs up into the lungs and body. Two smaller groups widen the picture a little. A retrospective series covered children in a cardiac intensive care unit with critical congenital heart disease, pulmonary congestion, and inadequate urine output despite diuretic therapy, across 37 infusions, and its summary gives no rate. The valve surgery pilot started its infusion three hours after cardiopulmonary bypass, the heart-lung machine used during the operation. For carperitide, the 2025 meta-analysis made in-hospital mortality its primary outcome, which places every patient on a ward at the time the drip was given. None of these groups was a healthy person, and the out-patient infusions described under the next question come with no stated amounts. Every amount on this page was chosen for a person in one of those states, and watched by staff who could stop it.

Question 3

How was it given, how often, and for how long?

Accepted Answer

Nesiritide was mostly given by vein, though not always in the same pattern. A 2002 review records that across trials in more than 2000 patients, nesiritide was administered by single or repeated bolus injections, as well as by sustained infusions. A 2009 review adds that it has been used as single in-patient infusions, multiple out-patient infusions, and perioperatively, which means around the time of surgery. A 2005 review notes that the possibility of subcutaneous injections of nesiritide has been studied in both animals and humans, subcutaneous meaning under the skin, and gives no amounts for it. Durations in the trials ran from hours to days, with 72 hours in the surgical pilot and up to 168 hours in ASCEND-HF. Carperitide's summary records only the intravenous route, as an infusion for acute heart failure. Each of these patterns is a description of what was done in a setting, rather than a template.

Question 4

Did the amount given change the kidney or blood pressure findings?

Accepted Answer

On the kidneys, a 2015 analysis says it did. It pooled fifteen randomised trials of patients with heart failure. High doses of nesiritide were strongly tied to worse kidney function, at a relative risk of 1.54. Standard and low doses showed no clear difference from other care. The authors concluded that nesiritide may have a dose-dependent effect on kidney function in these patients. On blood pressure, a 2001 review of trials in patients called dose-related low blood pressure the major side effect. VMAC picked its regimen partly to keep low blood pressure with symptoms uncommon. A 2016 meta-analysis of randomised trials found no added need for dialysis after low-dose nesiritide. These are links across trial groups rather than a threshold, and the summaries do not define the dose bands in figures. How the kidney and pressure harms played out overall is weighed on the Natriuretic peptide safety page.

Question 5

Is there a natriuretic peptide dosage chart?

Accepted Answer

No, and the charts that turn up in searches are almost always reading charts, which list blood concentrations rather than amounts given. A 2026 pooled analysis of 18,216 heart failure trial participants reported a median N-terminal pro-B-type natriuretic peptide of 987 pg/mL, with the middle half running from 517 to 1,781. The 2018 PARAGON-HF trial recorded an interquartile range of 464-1610 for the same marker, the range covering the middle half of its patients. A picogram is a trillionth of a gram, and those figures describe how much of the heart's own hormone was circulating in a millilitre of blood. They are the size of a signal, not an amount anyone took. Treating 987 pg/mL as a dose would be like treating a temperature reading as an amount of heat to add. What a reading means is the subject of the Natriuretic peptide overview.

Question 6

Do medicines that raise the body's own BNP count as natriuretic peptide dosing?

Accepted Answer

No. They are the indirect route, because they slow the breakdown of the body's own BNP, whereas a nesiritide drip adds more of it. A 2018 review describes this as the prevention of BNP degradation by angiotensin receptor/neprilysin inhibitors, a class whose best-known member is sacubitril/valsartan. In the 2026 PRAISE-MR trial of 84 patients, target dose was achieved in 60% of patients, with symptomatic hypotension as the primary titration-limiting factor. Titration means stepping a dose up until a target is reached or a side effect stops it. Four in ten never reached the target, which shows a dose there is an individual end point rather than one number. These are approved prescription medicines with their own labels. Their amounts describe them, and none of those amounts is a dose of BNP.

Question 7

What amounts of other medicines were judged by a natriuretic peptide reading?

Accepted Answer

Many, because a reading is a common way to tell whether a heart medicine is easing strain. In HARP-III, compared with irbesartan, sacubitril/valsartan lowered N terminal of prohormone brain natriuretic peptide by 18% on average across the study, in 414 people with kidney disease. The 2025 LEAF-CHF trial gave febuxostat, a medicine that lowers uric acid, for 24 weeks, and found it did not reduce plasma BNP levels at week 24 in patients with chronic heart failure. A 2019 meta-analysis found a levosimendan infusion in acute heart failure patients appeared to reduce BNP regardless of the comparator, except dopamine. Each figure is a dose of something else, and the natriuretic peptide is the gauge being read. A medicine that moves the gauge is not thereby a natriuretic peptide.

Question 8

What amounts were used in the animal work, and why do they not convert?

Accepted Answer

The rat studies state amounts per kilogram of body weight, and they show how the word natriuretic, meaning salt-shedding, can itself become a yardstick for dosing. A 2014 rat study compared finerenone and eplerenone, two medicines that block a salt-retaining hormone, at equinatriuretic doses, meaning amounts chosen to make the rats lose the same amount of salt. In rats with heart failure after a blocked coronary artery, finerenone at 1 mg·kg·d, but not eplerenone at 100 mg·kg·d, reduced plasma prohormone of brain natriuretic peptide levels. A 2001 study in salt-sensitive rats fed an 8% salt diet used benazepril 10 mg/kg alone, valsartan 30 mg/kg alone, or the two combined at lower amounts. Those are rat amounts of other medicines. Converting any of them to a person is not valid, and this page does not do it.

Question 9

What is given in the natriuretic receptor imaging study?

Accepted Answer

A radioactive tracer that seeks out one of the receptors natriuretic peptides bind to, given in a dosimetry study, and dosimetry is the measurement of radiation dose to each organ. The registry entry is titled PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Volunteer - Dosimetry Study). Its recorded status is recruiting, in an early phase 1 design. Carotid atherosclerosis is fatty build-up in the main neck arteries, and PET is a scan that tracks where a tracer collects. The dose in question there is a dose of radiation, measured so that a scan can be judged acceptable, and it is a different question from any dose of a hormone. With no result posted among these sources, that study describes a measurement being planned rather than a figure anyone can read.

Question 10

Does an approved schedule apply to research-grade natriuretic peptide?

Accepted Answer

No. Nesiritide was approved by the FDA in 2001 for patients with ADHF who have dyspnea at rest or with minimal exertion. A 2007 review called it a reasonable treatment adjunct only when used for approved indications and according to recommended dosage and administration regimens. Those regimens belong to the hospital product, made under its own controls and given into a vein by staff who can stop it. The labelled schedule is not quoted in the summaries behind this page, so this page does not state it, and the VMAC rates above are one trial's choice rather than a label. Even for that hospital product the evidence is unsettled, and the 2025 analysis concluded carperitide may not be superior to noncarperitide therapy in reducing in-hospital mortality rates or improving long-term outcomes. A vial sold as a research compound carries no label, no stated schedule and no monitoring, and no figure from a hospital setting reaches it.

Question 11

Why are study amounts not a protocol?

Accepted Answer

Because even inside the trials, the amount was one variable among several. The 2006 mortality meta-analysis said further analysis adjusted for nesiritide dose, duration of infusion, concurrent use of inotropes, heart failure stage, and arrhythmias may reveal subgroups in jeopardy. Inotropes are medicines that make the heart pump harder. Put plainly, the pooled trials could not separate the effect of the amount from who received it and alongside what. The 2025 LEAF-CHF trial found the fall in BNP was greater with febuxostat at weeks 4, 8, 12, 16 and 20, and yet no different by its end point at week 24. A dose that moves a reading at one week and not at another is a study result with conditions attached rather than a protocol. A rate lifted out of these trials and applied to a different person, in a different setting, would carry none of those conditions with it.

Study	Patients	Amount reported	Duration
VMAC	Adults in hospital, decompensated heart failure	0.2 µg/kg bolus, then 0.01 µg/kg/min	Not stated in summary
PRECEDENT	255 adults in hospital	0.015 or 0.03 µg/kg/min (dobutamine arm 5 µg/kg/min or more)	Not stated in summary
Valve surgery pilot	9 given nesiritide, 10 placebo	0.01 µg/kg/min	72 hours
ASCEND-HF	Adults in hospital, acute heart failure	Not stated in summary	24 to 168 hours
ROSE-AHF	Acute heart failure with kidney dysfunction	Low dose, no figure in summary	72 hours
Carperitide meta-analysis	Acute heart failure, nine studies	Not stated in summary	Not stated in summary

Study	Rats	Medicine	Amount
2014 study	Heart failure after a blocked coronary artery	Finerenone	1 mg·kg·d
2014 study	Heart failure after a blocked coronary artery	Eplerenone	100 mg·kg·d
2001 study	Salt-sensitive, 8% salt diet	Benazepril	10 mg/kg alone
2001 study	Salt-sensitive, 8% salt diet	Valsartan	30 mg/kg alone
2001 study	Salt-sensitive, 8% salt diet	Benazepril + valsartan	Lower amounts, combined

Natriuretic peptide protocols in the published literature